Pulmicort Nebuamp · DIN 02229099 · 0.125mg/mL · Inh suspension
Limited Use — Reason for Use code 260, 261, 262, 263, 264 requiredMarketed · checked 2026-09-18
StatusLimited Use — Reason for Use code 260, 261, 262, 263, 264 required
Write on scriptLU code 260, 261, 262, 263, 264 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 260, 261, 262, 263, 264
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 260
Children aged 6 years or less;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 261
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 262
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 263
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 264
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
Savings card: innoviCares lists Pulmicort Nebuamp (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Pulmicort Nebuamp · DIN 02229099
Manufacturer: AstraZeneca; listing date 1998-12-31
Health Canada: Marketed since 2000-01-29 · brand PULMICORT NEBUAMP 0.125 MG/ML · ATC R03BA02 BUDESONIDE · form Suspension · route Inhalation · ingredients BUDESONIDE 0.125 MG/ML · company Astrazeneca canada inc · schedule Prescription
Ministry pays: $0.1143 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43511 · Verify on the e-Formulary ↗ (DIN 02229099)
Source record
DIN 02229099: Pulmicort Nebuamp
Raw flags: sec12=Y, sec3=Y
Item: 680400072; group id 704; item number 1737; lccId 00107; manufacturer id AZC
Source form: Inh Susp; strength: 0.125mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.2778; ministry $0.1143
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02229099
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43511
Interchangeable products
Taro-Budesonide · DIN 02494264 · $0.1143
Teva-Budesonide · DIN 02465949 · $0.1143
Shortage status: resolved shortage (ended 2023-04-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02229099
Shortage record checked 2026-09-13T08:10:21.292534+00:00